Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

Do the Best Coronary Revascularization Prior TAVR

The presence of coronary artery disease (CAD) in patients with aortic stenosis is high, reaching 50% to70%...
solaci -
Learn More
Structural heart disease

TAVR in Patients with Classical Low Flow, Low Gradient

Classical symptomatic low-flow, low-gradient (LFLG) severe aortic stenosis is associated with low survival rates at 3 years (<50%)....
solaci -
Learn More
Other

Diastolic Dysfunction Should Be Considered in TAVR

Aortic stenosis increases afterload creating hypertrophy as a compensation mechanism to maintain minute volume. This leads to...
solaci -
Learn More
Structural heart disease

Delayed Coronary Obstruction After TAVR: A Complication We Had Not Considered

Delayed coronary obstruction (after TAVR, outside the cath lab) is a rare complication with high mortality rates,...
solaci -
Learn More
Structural heart disease

Which Low-Flow, Low-Gradient Patients Benefit from Valve Replacement?

A mean gradient ≥40 mmHg, an aortic valve area ≤1 cm², or a combination of both, during dobutamine stress...
solaci -
Learn More
Structural heart disease

Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As...
solaci -
Learn More
STRUCTURAL HEART DISEASE

NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising

At 5 years, there were no differences in all-cause death, stroke, acute myocardial infarction, or all of these...
solaci -
Learn More
Structural heart disease

Permanent Pacemaker: still TAVR’s Aquila’s Heel

TAVR has shown benefits in high risk patients (prohibitive) and in intermediate risk patients, but the need for permanent...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy